An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation

Pfizer

Status and phase: Completed; Phase 3

Conditions: Smoking Cessation

Treatments: Drug: varenicline (CP-526,555)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00143325

A3051044

Details and patient eligibility

About

Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects must have smoked an average of at least 15 cigarettes per day during the past year and over the month prior to the screening visit, with no period of abstinence greater than 3 months in the past year.

Exclusion criteria

• Subjects with clinically significant cardiovascular disease in the past 6 months.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind